Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 19 Mar 2026 | Marc Lemaitre Director-General | Next generation of European public-private partnerships under FP10 / Horizon Europe | SRC |
| 19 Mar 2026 | Marc Lemaitre Director-General | Next generation of European public-private partnerships under FP10 / Horizon Europe | — |
| 15 Jan 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views with private members of the Innovative Health Initiative Joint Undertaking (IHI-JU). | SRC |
| 15 Jan 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views with private members of the Innovative Health Initiative Joint Undertaking (IHI-JU). | — |
| 15 Jan 2026 | Maria Pilar Aguar Fernandez Director | Exchange of views with private members of the Innovative Health Initiative Joint Undertaking (IHI-JU). | — |
| 15 Jan 2026 | Maria Pilar Aguar Fernandez Director | Exchange of views with private members of the Innovative Health Initiative Joint Undertaking (IHI-JU). | SRC |
| 25 Nov 2025 | Massimo Suardi Director | Continuing need for Member States to prioritise investments in prevention amidst current political, security and economic headwinds | — |
| 25 Nov 2025 | Massimo Suardi Director | Continuing need for Member States to prioritise investments in prevention amidst current political, security and economic headwinds | SRC |
| 03 Oct 2025 | Olga Solomon Head of Unit | The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition. | — |
| 03 Oct 2025 | Olga Solomon Head of Unit | The discussion focused on simplifying Annex II to foster innovation while aligning with ICH guidelines, with ideas for legacy products to gradually transition. | SRC |
| 02 Oct 2025 | Olivér Várhelyi Commissioner | All pressing portfolio topics | SRC |
| 02 Oct 2025 | Jana Dabbelt Cabinet member | All pressing portfolio topics | SRC |
| 02 Oct 2025 | Jana Dabbelt Cabinet member | All pressing portfolio topics | — |
| 03 Jun 2025 | Florika Fink-Hooijer Director-General | Immunisation return on investment for societies | — |
| 03 Jun 2025 | Florika Fink-Hooijer Director-General | Immunisation return on investment for societies | SRC |
| 27 May 2025 | Olivér Várhelyi Commissioner | Contribution of Vaccines industry to European health union priorities | — |
| 27 May 2025 | Olivér Várhelyi Commissioner | Contribution of Vaccines industry to European health union priorities | SRC |
| 27 May 2025 | Laszlo Andrejko Cabinet member | Contribution of Vaccines industry to European health union priorities | SRC |
| 06 Nov 2020 | Stella Kyriakides Commissioner | Videoconference with Pharmaceutical Industry Associations to discuss shortages of medicines and medical devices including diagnostic tests in the context of COVID-19 pandemic | — |
| 06 Nov 2020 | Stella Kyriakides Commissioner | Videoconference with Pharmaceutical Industry Associations to discuss shortages of medicines and medical devices including diagnostic tests in the context of COVID-19 pandemic | SRC |
| 30 Sept 2020 | Karolina Herbout-Borczak Cabinet member | Call with pharmaceutical and medical device supply Chain on COVID-19 | SRC |
| 30 Sept 2020 | Karolina Herbout-Borczak Cabinet member | Call with pharmaceutical and medical device supply Chain on COVID-19 | — |
| 29 Jun 2020 | Stella Kyriakides Commissioner | Videoconference with Pharmaceutical Industry Associations to discuss shortages of medicines and medical devices including diagnostic tests in the context of COVID-19 pandemic | — |
| 29 Jun 2020 | Stella Kyriakides Commissioner | Call with pharmaceutical and medical device industry associations on COVID-19 | SRC |
| 29 Jun 2020 | Stella Kyriakides Commissioner | Call with pharmaceutical and medical device industry associations on COVID-19 | — |
Mission & Goals
Vaccines Europe mission is to foster innovation and value recognition of lifecourse immunisation in Europe to protect people against evolving health challenges.
EU Legislative Interests
Any health or pharmaceutical policy stemming from the European Institutions such as industrial policy, European Semester, Horizon Europe Research Programme, EU4Health programme, HTA policy, IP policy, Pharmaceutical strategy, One Health Approach to tackle AMR, paediatrics legislation, (COVID-19) outbreak measures, pandemic preparedness. Vaccines Europe also follows Clinical Trials regulation, European’s Beating Cancer plan, SafeHeartsPlan, HERA, EMA, ECDC and Serious Cross Border Threats to Health regulations.
Communication Activities
Vaccines Europe communication activities include: - Publishing policy positions and new evidence (reports, leaflets, infographics) on the policies mentioned above - Publishing blog posts to share opinions - Participating and contributing in events organised by other stakeholders on relevant topics - Organising events including Vaccines Europe members and external stakeholders - Disseminating our key messages through media partnerships and social media
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Vaccines Europe operates as a specialised group within the European Federation of Pharmaceutical Industries and Associations – EFPIA-, which operates as the representative organisation of the pharmaceutical industry in Europe.
Organisation Members
https://www.vaccineseurope.eu/about-us/our-members/ Vaccines Europe's constituent entities include 16 member companies